Uncategorized Archives - Page 8 of 8 - Fennec Pharmaceuticals : Fennec Pharmaceuticals

Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results

Posted on August 9, 2019 (August 8, 2019) by mgowland

Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention […]

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

Posted on June 19, 2019 (June 19, 2019) by mgowland

Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results

Posted on May 9, 2019 by mgowland

Fennec Provides Business Update and Announces First Quarter 2019 Financial Results Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty […]